dual GIP/GLP-1 agonistGLP-1 AgonistsVerified Match
Tirzepatide
A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved as Mounjaro/Zepbound. Achieves up to 22.5% weight loss. First-in-class dual incretin agonist.
weight-lossblood-sugar-controlappetite-suppressiondual-agonistFDA-approved
3D Structure
3D Structure
4813.45 Da
Lab Tested
Yes
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch#G202411
Total Tests141
Unique Vendors136
Vendor Comparison
| Vendor | Status |
|---|---|
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
Analysis Summary
Purity Standard
No purity dataLab Reports
141 reports on file
Summary
A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved as Mounjaro/Zepbound. Achieves up to 22.5% weight loss. First-in-class dual incretin agonist.